Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1


30 Sep 2019


Poster Display session 3



Tumour Site

Non-Small Cell Lung Cancer


Vivek Radhakrishnan


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


V. Radhakrishnan1, S. Banavali2, S. Gupta3, A. Kumar4, C.D. Deshmukh5, S. Nag6, S.K. Beniwal7, M. Gopichand8, R. Naik9, K.C. Lakshmaiah10, D. Mandavia4, M. Ramchandra4, K. Prabhash2

Author affiliations

  • 1 Hematology-oncology, TMC Kolkata, 700160 - Kolkata/IN
  • 2 Oncology, Tata Memorial Hospital, 400012 - Mumbai/IN
  • 3 Oncology, Tata Memorial Hospital Centre, 400012 - Mumbai/IN
  • 4 Oncology, Aurigene Discovery Technologies Limited, 560100 - Bangalore/IN
  • 5 Medical Oncology, Deenanath Mangeshkar Hospital & Research Centre, 411004 - Pune/IN
  • 6 Medical Oncology, Jehangir Hospital, 411001 - Pune/IN
  • 7 Medical Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, 334001 - Bikaner/IN
  • 8 Surgical Oncology, City cancer Center, 520002 - Vijayawada/IN
  • 9 Oncology, HCG Bangalore Institute of Oncology Speciality Centre, 560027 - Bangalore/IN
  • 10 Oncology, Srinivasam Hospital, Bangalore/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3012


VISTA and PD-1/PD-L1 are independent immune checkpoints. Preclinical studies demonstrate synergism with dual blockade of these pathways. CA-170 is an oral agent targeting both VISTA and PD-L1. A Phase I dose escalation study (NCT02812875) has shown acceptable safety up to 2400 mg total daily dosage. Early results from current Phase II have been presented previously (Proc. SITC 2018; P715).


The current phase II randomized patients with multiple tumor types (Head & Neck Cancer, Squamous-NSCLC, Non-Squamous-NSCLC, MSI-H+ solid tumors and Hodgkin Lymphoma) to 400mg versus 800mg. Key eligibility included: age ≥ 18 years, ECOG ≤1, adequate organ function, no previous exposure to IO agents and 1-3 lines of prior therapy. Primary objective is response rate assessment by a central radiologist. Secondary endpoints include additional efficacy and safety endpoints.


The study enrolled 62 IO-naïve patients over 8 months, from February through October 2018. Efficacy population included 15 non-squamous NSCLC patients, who had received a median of 2 lines of prior therapy. Additionally, median time from diagnosis was ∼ 14 months, and much higher than 8-9 months in earlier 2nd line IO antibody trials in NSCLC. Eight and seven patients, respectively, received 400 and 800 mg. Demographics and baseline characteristics of both groups are similar. While none of the non-squamous NSCLC patients achieved 30% cut-off for response by RECIST, six had tumor reductions, up to 20%. Analyzed by dose groups, CBR and median PFS were 75% and 19.5 weeks in the 400 mg group versus 50% and 7.9 weeks in the 800 mg group. Superior efficacy at 400mg was also observed in other tumor types. The AEs and SAEs have been as expected without any concerns or major events.


Excellent CBR and PFS have been observed at 400 mg. Superior effects at 400 mg versus 800 mg dosage may likely be due to a bell-shaped response curve, previously noted in pre-clinical studies with possible activation-induced T cell death at higher doses. CA-170 also appears to have significant safety benefit, compared to IO antibodies. These data position oral IO agents such as CA-170 for evaluation in adjuvant and/or maintenance settings in non-squamous NSCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Aurigene Discovery Technologies Limited.


Aurigene Discovery Technologies Limited.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.